Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine/Busulfan Conditioning with ATG/Tacrolimus/Methotrexate Prophylaxis in Myeloid Malignancies
NCT00346359Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2006
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, fludarabine, antithymocyte globulin rabbit, tacrolimus, methotrexate in chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), sponsored by Fred Hutchinson Cancer Center. Started Mar 2006; status: completed.
02
Drugs
busulfanfludarabineantithymocyte globulin rabbittacrolimusmethotrexate
03
Conditions
chronic myelogenous leukemia (CML)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT00346359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00346359.